Table 2.
Baseline Clinical, Hemodynamic, and General Echocardiographic Variables
| Variable | No Adverse Events (n=29) | With Adverse Events (n=36) | P |
|---|---|---|---|
| Male, % | 79 | 80 | NS |
| Mean age, y | 57±14 | 55±12 | NS |
| ICD/CRT, % | 25/3.5 | 32/3 | NS |
| Serum creatinine, mg/dL | 1.36±0.7 | 1.45±0.7 | NS |
| NT-proBNP, median pg/mL (IQR) | 4214 (2322–6438) | 4582 (2164–10565) | NS |
| hsCRP, mg/dL | 23.9±25 | 19.4±21.7 | NS |
| Hemodynamic indices | |||
| HR, bpm | 83±16 | 80±16 | NS |
| Systolic BP, mm Hg | 107±15 | 106±23 | NS |
| Systolic PAP, mm Hg | 49±12 | 48±16 | NS |
| CVP, mm Hg | 13±5 | 13±6 | NS |
| PCWP, mm Hg | 21±7 | 21±8 | NS |
| PVR, dynes/cm5 | 240±128 | 198±106 | NS |
| Cardiac index, L/(min · m2) | 2.0±0.5 | 2.0±0.8 | NS |
| Echocardiographic indices | |||
| LVEDV, mL | 220±87 | 246±126 | NS |
| LV ejection fraction, % | 25±11 | 27±10 | NS |
| Tricuspid valve regurgitation grade, n | <0.001 | ||
| 0 | 11 | 4 | |
| 1 | 9 | 5 | |
| 2 | 7 | 11 | |
| 3 | 2 | 7 | |
| 4 | 0 | 9 | |
| Tricuspid regurgitation VC, mm | 2.24 | 5.04 | <0.001 |
| Mitral valve regurgitation grade, n | NS | ||
| 0 | 7 | 5 | |
| 1 | 8 | 10 | |
| 2 | 6 | 11 | |
| 3 | 3 | 6 | |
| 4 | 5 | 4 | |
| Mitral regurgitation VC, mm | 3.47 | 3.88 | NS |
Data are presented as mean±SD unless otherwise indicated. BP indicates systemic arterial pressure; CVP, central venous pressure; HR, heart rate; hsCRP, high-sensitivity C-reactive protein; ICD/CRT, intracardiac defibrillator/cardiac resynchronization therapy; IQR, interquartile range; LVEDV, left ventricular end-diastolic volume; NT-proBNP, N-terminal pro-brain natriuretic peptide; PAP, pulmonary artery pressure; PCWP, pulmonary capillary wedge pressure; PVR, pulmonic vascular resistance; VC, vena contracta width.